Precigen, Inc. (PGEN)
7.48
+0.12
(+1.70%)
USD |
NASDAQ |
Oct 15, 10:03
Precigen Total Long Term Debt (Quarterly) : 97.29M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 97.29M |
| March 31, 2026 | 97.18M |
| December 31, 2025 | 97.15M |
| September 30, 2025 | 97.07M |
| June 30, 2025 | 4.223M |
| March 31, 2025 | 4.489M |
| December 31, 2024 | 4.546M |
| September 30, 2024 | 4.761M |
| June 30, 2024 | 5.072M |
| March 31, 2024 | 5.387M |
| December 31, 2023 | 5.895M |
| September 30, 2023 | 6.192M |
| June 30, 2023 | 6.545M |
| March 31, 2023 | 20.44M |
| December 31, 2022 | 50.21M |
| September 30, 2022 | 90.01M |
| June 30, 2022 | 206.77M |
| March 31, 2022 | 210.98M |
| December 31, 2021 | 188.68M |
| September 30, 2021 | 191.37M |
| June 30, 2021 | 189.10M |
| March 31, 2021 | 181.46M |
| December 31, 2020 | 179.63M |
| September 30, 2020 | 214.54M |
| June 30, 2020 | 244.52M |
| Date | Value |
|---|---|
| March 31, 2020 | 243.03M |
| December 31, 2019 | 228.11M |
| September 30, 2019 | 253.65M |
| June 30, 2019 | 251.70M |
| March 31, 2019 | 254.76M |
| December 31, 2018 | 211.70M |
| September 30, 2018 | 183.68M |
| June 30, 2018 | 7.762M |
| March 31, 2018 | 7.926M |
| December 31, 2017 | 8.037M |
| September 30, 2017 | 8.112M |
| June 30, 2017 | 8.118M |
| March 31, 2017 | 7.996M |
| December 31, 2016 | 7.948M |
| September 30, 2016 | 8.421M |
| June 30, 2016 | 8.021M |
| March 31, 2016 | 8.506M |
| December 31, 2015 | 8.528M |
| September 30, 2015 | 9.11M |
| June 30, 2015 | 9.467M |
| March 31, 2015 | 9.726M |
| December 31, 2014 | 10.38M |
| September 30, 2014 | 10.92M |
| June 30, 2014 | 2.001M |
| March 31, 2014 | 1.784M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 23.32M |
| Aldeyra Therapeutics, Inc. | 0.00 |
| Repligen Corp. | 671.62M |
| AC Immune SA | 5.085M |
| Amgen, Inc. | 57.30B |